Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Male Suicide and Metacognition (MSM)

11 de março de 2021 atualizado por: Jonothan Orson, Greater Manchester Mental Health NHS Foundation Trust

An Exploration of the Role of Metacognition and Masculinity in Men Experiencing Suicidality

Suicide is the act of killing oneself and accounts for one death every 40 seconds around the world. In the UK, over 75% of suicides are completed by men. Suicidal ideation is a symptom of depression and is assessed when diagnosing depressive disorder. Men are three times more likely to complete suicide than women but half as likely to be diagnosed with depression, and therefore risk missing out on potentially lifesaving treatments.

Men experiencing depression and associated suicidality are less likely to demonstrate traditional symptoms such as hopelessness and sadness, and more likely to engage in unhelpful coping strategies such as avoidance through over-working, substance misuse, or risk-taking behaviours, and may feel that they have lost control. Previous research has shown a link between rumination and increased suicidal intent.

Unhelpful coping strategies, distorted beliefs about uncontrollability, and thinking processes such as rumination, are central to the metacognitive model of psychological distress and are targeted in Metacognitive Therapy (MCT).

The aim of this project is to identify if any aspects of the thinking styles described above are present in a sample of men who are suicidal. The project will also explore beliefs about masculinity and how these beliefs might impact help-seeking.

In order to achieve these aims, 15 male service-users without a severe and enduring mental illness, who are receiving care from the Home Based Treatment Team following suicidal thoughts or actions, will be invited to take complete some questionnaires and partake in an interview.

Visão geral do estudo

Status

Desconhecido

Condições

Descrição detalhada

The reduction of suicide is a priority for the Department of Health and Social Care which recommends focusing research and interventions on high-risk groups, such as men. 75% of suicides in the UK are completed by men, it is the biggest killer of men under 45, and 12 men die by suicide each day.

Previous research shows that men may be more likely to mask their symptoms and avoid seeking help from friends, family and professionals. Literature suggests this could be due to the social stigma attached to mental ill health and society's traditional expectations of how men should behave. Evidence also suggests that men may be less likely to present with typical symptoms of depression, such as sadness or hopelessness, and be more likely to engage in activities like overworking, substance misuse, promiscuity and gambling. Studies exploring suicidality in adults have found that increased rumination is linked with higher suicidal intent, and that men in particular may experience accepting antidepressant medication as proof that they have 'lost control'.

Rumination, avoidance, maladaptive coping strategies, and beliefs about uncontrollability are known as 'metacognitions' and are targeted in Metacognitive Therapy (MCT). MCT has a growing evidence base for a range of psychological disorders, including anxiety and depression, and aims to reduce rumination, avoidance, worry, and maladaptive coping strategies, whilst supporting the individual to discover control.

There is a lack of research into how the thinking processes described above present in men who are at risk of suicide. This project aims to contribute to this knowledge base in order to discover whether Metacognitive Therapy (or brief metacognitive interventions) may be a viable treatment option for this population, and worthy of further research. This aim will be achieve by determining which, if any, metacognitions are present in a population of men who are suicidal.

Additionally, the project seeks to explore men's beliefs about masculinity and suicide; and how these beliefs along with the thinking styles previously described, may impact on help-seeking. This could inform future planning of engagement and interventions for this population.

Justification for this research can be found in national reports such as 'The Five Year Forward View' and the 'NHS Long Term Plan', both of which highlight suicide prevention, particularly in high-risk groups such as men, as a priority for clinicians and researchers; more locally, Greater Manchester Mental Health's NHS Foundation Trust's 'Research & Innovation Strategy' commits to conducting research into suicide prevention and improving patient safety.

Tipo de estudo

Observacional

Inscrição (Antecipado)

15

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Manchester, Reino Unido, M2553BL
        • Greater Manchester Mental Health NHS Foundation Trust

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

16 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Método de amostragem

Amostra Não Probabilística

População do estudo

Males aged 16+ who are receiving care from the Home Based Treatment Team following suicidal ideation or behaviour and have capacity to provide informed consent to take part.

Descrição

Inclusion Criteria:

  • Men aged 16+ who are currently receiving care from the Home Based Treatment Team and are experiencing suicidal thoughts and behaviours
  • Men with a primary mental health diagnosis of anxiety, depression, acute stress reaction or adjustment disorder, or men with no diagnosis at all
  • Men who are able to provide written, informed consent

Exclusion Criteria:

  • Women will not be eligible as the aim of this study is to investigate masculinity and its impact on suicidality and help-seeking
  • Diagnosis of a severe and enduring mental illness such as Schizophrenia or Bipolar Affective Disorder will be excluded, as their suicidality may be secondary to their diagnosis and more suitable to research within that context
  • Non-English-speaking as interviews and assessments will be completed in the English language and are not validated in other languages.
  • Unable to provide written, informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cognitive Attentional Syndrome Scale (CAS-1)
Prazo: 2 minutes
Self-report questionnaire, measuring time spent engaging in metacognitive strategies and conviction in metacognitive beliefs. E.g. First section asks individuals how much time they have spent 'dwelling' on their problems on a scale of 0-8, 0 being none of the time and 8 being all of the time. The latter section asks people to rate beliefs about worry, e.g. 'worrying too much could harm me', on a scale of 0-100 ('0' meaning, 'I do not believe this at all' and '100' meaning, 'I am completely convinced this is true'. There is no 'better' or 'worse' outcome, measure is simply used to describe the population of participants and any common features of the sample.
2 minutes
Metacognitions Questionnaire - 30 (MCQ-30)
Prazo: 5 minutes
A self-report questionnaire designed to measure an individual's metacognitive beliefs. The individual rates their agreement with statements such as, 'my worrying is dangerous for me', on a scale of 1-4, 1 meaning 'do not agree' and 4 meaning, 'agree very much'. There is no 'better' or 'worse' outcome, measure is simply used to describe the population of participants and any common features of the sample.
5 minutes
Cognitions Concerning Suicide Scale (CCSS)
Prazo: 5 minutes
Self-report questionnaire, where individuals rate how much they agree with beliefs about suicide, such as, 'everyone has the right to commit suicide'; individuals tick whether they 'strongly disagree, disagree, neutral, agree, or strongly agree'. There is no 'better' or 'worse' outcome, measure is simply used to describe the population of participants and any common features of the sample.
5 minutes
Masculine Behaviour Scale (MBS)
Prazo: 1 minute
Self-report questionnaire exploring beliefs about masculinity. Individuals rate their agreement with statements about masculinity, such as, 'I don't usually discuss my feelings or emotions with others' by ticking, 'agree, slightly agree, neither agree nor disagree, slightly disagree, disagree'. There is no 'better' or 'worse' outcome, measure is simply used to describe the population of participants and any common features of the sample.
1 minute
Qualitative Interview
Prazo: 45 minutes
Interview conducted using the Metacognitive Profiling Interview Schedule
45 minutes

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jonothan Orson, MA Nursing, Greater Manchester Mental Health NHS Foundation Trust

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Antecipado)

1 de abril de 2021

Conclusão Primária (Antecipado)

1 de agosto de 2021

Conclusão do estudo (Antecipado)

1 de janeiro de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

5 de março de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de março de 2021

Primeira postagem (Real)

12 de março de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de março de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de março de 2021

Última verificação

1 de março de 2021

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • F485s

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

IPD will not be shared. Records will be accessed by the Principal Investigator and other regulatory bodies only for the purpose of audit or investigation.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever